Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunomodulation using bacterial enterotoxins.

C P Simmons1, M Ghaem-Magami, L Petrovska

  • 1Department of Biochemistry, Imperial College of Science Technology and Medicine, South Kensington, London SW7 2AZ, UK. c.simmons@ic.ac.uk

Scandinavian Journal of Immunology
|March 17, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiomic analysis identifies glutaminolysis-dependent metabolic enhancement of immune memory utilised for vaccine development.

Nature communications·2026
Same author

Dysregulation of macrophage PEPD in obesity determines adipose tissue fibro-inflammation and insulin resistance.

Nature metabolism·2022
Same author

Three phylogenetic groups have driven the recent population expansion of Cryptococcus neoformans.

Nature communications·2019
Same author

Farewell Stan Stanley Falkow: 1934-2018.

Environmental microbiology·2018
Same author

Point-prevalence survey of carbapenemase-producing Enterobacteriaceae and vancomycin-resistant enterococci in adult inpatients in a university teaching hospital in the UK.

The Journal of hospital infection·2018
Same author

Erratum: Antimicrobial resistance in human populations: challenges and opportunities - ERRATUM.

Global health, epidemiology and genomics·2018
Same journal

Recent Thymic Emigrant Levels in Inborn Errors of Immunity: Is Their Diagnostic Value Greater Than We Think?

Scandinavian journal of immunology·2026
Same journal

The EBNA-1 Conundrum: Does Epstein-Barr Virus Invoke Autoimmune Pathology in a Population Subset by Poorly Purine-Loading Its Major Latency-Maintaining Transcript?

Scandinavian journal of immunology·2026
Same journal

Unsupervised Flow Cytometry Reveals a Constant Shift Towards Activated CD4<sup>+</sup> T Cell Subsets in APECED.

Scandinavian journal of immunology·2026
Same journal

RETRACTION: Interleukin-13 Induces T Helper Type 2 Immune Responses in OVA-Immunized BALB/c Mice Bearing a T Cell Lymphoma.

Scandinavian journal of immunology·2026
Same journal

Development of a Detection Method for Soluble Urokinase-Type Plasminogen Activator Receptor and Its Application in Predicting Prognosis of Severe COVID-19.

Scandinavian journal of immunology·2026
Same journal

Crohn's Disease Enteritis: Pathophysiological Mechanisms and Therapeutic Approaches.

Scandinavian journal of immunology·2026
See all related articles

Mucosal immune tolerance can be induced via vaccination. Bacterial toxins like cholera toxin can enhance immune responses, aiding mucosal vaccine development for tolerance induction.

Area of Science:

  • Immunology
  • Microbiology
  • Vaccinology

Background:

  • The mucosal immune system typically exhibits immunologic unresponsiveness (tolerance).
  • Mucosal vaccination can deliberately induce immune suppression.
  • Certain bacterial toxins, such as cholera toxin and heat-labile toxin from Escherichia coli, are exceptions, acting as immunogens and immunomodulators.

Purpose of the Study:

  • To review the structural and biological characteristics of specific bacterial toxins.
  • To explore the application of these toxins in inducing tolerance.
  • To examine their role in developing mucosal vaccines.

Main Methods:

  • Literature review of studies on bacterial toxins and mucosal immunity.
  • Analysis of structural and biological properties of cholera toxin and E. coli heat-labile toxin.

Related Experiment Videos

  • Examination of case examples in tolerance induction and mucosal vaccine design.

    • Main Results:

    • Bacterial toxins can overcome mucosal tolerance.
    • These toxins act as potent adjuvants for codelivered antigens.
    • Their properties are being leveraged for advanced vaccine strategies.

    Conclusions:

    • Bacterial toxins possess unique properties exploitable for mucosal vaccine development.
    • These toxins can be utilized to induce specific immune responses or tolerance at mucosal surfaces.
    • Further research into these toxins holds promise for innovative immunotherapies and vaccines.